Skip to Content

Franklin Genomic Advancements ETF HELX

Quantitative rating as of

Morningstar’s Analysis HELX

Will HELX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.



Weakness in Franklin Genomic Advancements ETF's Process and People Pillar ratings limits this strategy to a Morningstar Quantitative Rating of Negative. The portfolio maintains a sizable cost advantage over competitors, priced within the least expensive fee quintile among peers.

Unlock our full analysis with Morningstar Investor